Hui Y F, Ignoffo R J
Department of Clinical Pharmacy, University of California, San Francisco, USA.
Cancer Pract. 1997 Mar-Apr;5(2):124-7.
Docetaxel is a taxane that disrupts the equilibrium in the polymerization and depolymerization of microtubules, thus inhibiting cell growth. This agent is indicated for the treatment of anthracycline-resistant metastatic breast cancer. The dose-limiting adverse effect is neutropenia, but febrile neutropenia is uncommon. Like paclitaxel, docetaxel is very active in patients with both chemotherapy-resistant and refractory metastatic breast cancer. Although the mechanism of action, spectrum of activity, and side effect profile of this agent are similar to those of paclitaxel, docetaxel may be efficacious in patients with metastatic breast cancer who have become resistant or refractory to paclitaxel therapy. However, more studies are warranted before the role of docetaxel is defined in patients with paclitaxel-resistant breast cancer.
多西他赛是一种紫杉烷类药物，它会破坏微管聚合和解聚的平衡，从而抑制细胞生长。该药物适用于治疗对蒽环类药物耐药的转移性乳腺癌。剂量限制性不良反应是中性粒细胞减少，但发热性中性粒细胞减少并不常见。与紫杉醇一样，多西他赛在化疗耐药和难治性转移性乳腺癌患者中都非常有效。尽管该药物的作用机制、活性谱和副作用特征与紫杉醇相似，但多西他赛可能对已对紫杉醇治疗产生耐药或难治的转移性乳腺癌患者有效。然而，在确定多西他赛在紫杉醇耐药乳腺癌患者中的作用之前，还需要更多的研究。
